CD19 and diffuse large B-cell lymphoma: Herein, we describe a patient with R/R DLBCL who underwent sequential pseudoallogeneic CAR20/22/19 T-cell therapy after relapsing following immunochemotherapy, ASCT, radiotherapy, autologous CD19 CAR-T (auto-CD19 CAR-T), and allo-HSCT.